Press Releases CSL Limited

Equities

CSL

AU000000CSL8

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-03 am EDT			5-day change	1st Jan Change
281.3 ^AUD	+0.44%		+0.25%	-1.85%

May. 30	US nears deal to fund Moderna's bird flu vaccine trial, FT reports	RE
May. 27	US, European nations consider vaccinating workers exposed to bird flu	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CSL : Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand	Apr. 30	PU
CSL : Shareholder Information Meetings	Apr. 22	PU
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build “Australia’s next CSL”	Apr. 17	PU
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure	Mar. 19	AQ
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	Feb. 26	AQ
CSL - Half year reported NPATA US$2 billion-1,-2 Up 13% at constant currency-3	Feb. 14	AQ
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³	Feb. 12	AQ
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112	Feb. 12	AQ
CSL Limited - Notice of Investor, Analyst Briefing 2024 Half Year Result	Jan. 31	AQ
CSL - Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options	Jan. 17	AQ
CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe	Jan. 04	AQ
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA 4-and 5-Gram Vials	Jan. 03	AQ
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster	Dec. 22	AQ
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older	Dec. 21	AQ
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance	Dec. 15	AQ
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults	Nov. 29	AQ
Iron Deficiency Day 2023, CSL Vifor calls for access to iron deficiency diagnosis and treatment	Nov. 27	AQ
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment	Nov. 24	AQ
CSL and uniQure Win 2023 Prix Galien USA Award	23-10-30	AQ
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B	23-10-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CSL Limited

Equities

CSL

AU000000CSL8

Press Releases

Filters